Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01100502 · FLOW

Participant flow

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) · Source last updated 2021-05-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    FG000
    title
    Brentuximab Vedotin
  2. description
    placebo every 3 weeks by IV infusion
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        18
      2. group Id
        FG001
        num Subjects
        25
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        13
      2. group Id
        FG001
        num Subjects
        28
      type
      Lost to Follow-up
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      Site request to end participation in study
    4. reasons
      1. group Id
        FG000
        num Subjects
        45
      2. group Id
        FG001
        num Subjects
        40
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        165
      2. group Id
        FG001
        num Subjects
        164
      type
      STARTED
    2. achievements
      1. comment
        Completed due to study closure by sponsor
        group Id
        FG000
        num Subjects
        89
      2. comment
        Completed due to study closure by sponsor
        group Id
        FG001
        num Subjects
        70
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        76
      2. group Id
        FG001
        num Subjects
        94
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Apr 2010-Aug 2014
Complete source fields
groups
  1. description
    brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
    id
    FG000
    title
    Brentuximab Vedotin
  2. description
    placebo every 3 weeks by IV infusion
    id
    FG001
    title
    Placebo
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        18
      2. group Id
        FG001
        num Subjects
        25
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        13
      2. group Id
        FG001
        num Subjects
        28
      type
      Lost to Follow-up
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      Site request to end participation in study
    4. reasons
      1. group Id
        FG000
        num Subjects
        45
      2. group Id
        FG001
        num Subjects
        40
      type
      Death
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        165
      2. group Id
        FG001
        num Subjects
        164
      type
      STARTED
    2. achievements
      1. comment
        Completed due to study closure by sponsor
        group Id
        FG000
        num Subjects
        89
      2. comment
        Completed due to study closure by sponsor
        group Id
        FG001
        num Subjects
        70
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        76
      2. group Id
        FG001
        num Subjects
        94
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Apr 2010-Aug 2014

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice